osimertinib
astrazeneca
['tagrisso', 'nsclc', 'sclc', 'astrazeneca', '$azn']
astrazeneca's tagrisso lowers risk of death by 51% in adjuvant nsclc study $azn #asco23 
The latest global #pharma news, insights, analysis, and views providing you with an information edge.  FirstWord Pharma. Where people who know first, go first.